New combo therapy aims to extend life for blood cancer patients who stopped responding to standard pills

NCT ID NCT06104566

Recruiting now Disease control Sponsor: Ascentage Pharma Group Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 25 times

Summary

This study tests whether adding a new drug called lisaftoclax to standard BTK inhibitor therapy helps people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer without their cancer getting worse. About 400 adults who have been on a BTK inhibitor for at least 12 months will be randomly assigned to either continue their current BTK inhibitor alone or add lisaftoclax. The main goal is to see if the combination delays cancer progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLL/SLL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Kaluga Regional Clinical Research
RECRUITING

Kaluga, 246007, Russia

Contact
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact

Conditions

Explore the condition pages connected to this study.

CLL/SLL